Skip to main content
Jacalyn Rosenblatt, MD, Hematology, Boston, MA, Beth Israel Deaconess Medical Center

JacalynMRosenblattMD

Hematology Boston, MA

Assistant Professor, Medicine-Beth Israel Deaconess Medical Center, Harvard Medical School

Dr. Rosenblatt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Rosenblatt's full profile

Already have an account?

Education & Training

  • McGill University Faculty of Medicine
    McGill University Faculty of MedicineClass of 1997

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2003 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • T Cells Educated By DC/AML Fusions in the Context of 4-1BB Costimulation As a Potent Strategy for Adoptive Cellular Therapy
    Jacalyn Rosenblatt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma
    Jacalyn Rosenblatt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Development of HHV-6-Specific Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of CD4+ T Cells
    Jacalyn Rosenblatt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • A Novel Monoclonal Antibody Combination Plus DC/AML Fusion Vaccine Eradicates AML in an Immunocompetent Murine Model 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Mult... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • BIDMC Marks International Day of Women and Girls in Science
    BIDMC Marks International Day of Women and Girls in ScienceFebruary 11th, 2020
  • Emerging Therapies for Multiple Myeloma
    Emerging Therapies for Multiple MyelomaMay 30th, 2019
  • Taking a New Shot at Tumor Vaccines
    Taking a New Shot at Tumor VaccinesMarch 6th, 2019
  • Join now to see all

Other Languages

  • French

Hospital Affiliations